- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06265727
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients With Advanced Solid Tumors
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4.
The main questions it aims to answer are:
What is the the safe and effective dose of CRB-701 when used alone? What cancers can be treated effectively with CRB-701?
Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701 on its own. They will have blood tests and other assessments to measure whether CRB-701 will have CT or MRI scans to measure the effect on tumors.
Study Overview
Detailed Description
This is a three-part open-label, Phase 1/2 clinical trial designed to evaluate the safety, PK, and efficacy of CRB-701 in participants with advanced solid tumors expressing nectin-4.
Part A will include solid tumor types known to express nectin-4. Dose escalation will be guided by the Bayesian optimal interval (BOIN) design to determine the MTD of CRB-701. Four (4) dose groups are pre-determined. Dose escalation/de-escalation decisions are made based on the occurrence of DLT.
Part B will determine the RP2D of CRB-701 by evaluating two dose levels of CRB-701 by using a time-to-event Bayesian optimal Phase 2 (TOP) study design to optimize the dose of CRB-701 in one or more separate cohorts of participants with nectin-4-positive tumors.
During Part C, the RP2D dose of CRB-701 will be evaluated in five planned expansion cohorts using Simon's optimal two-stage design.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Ian Hodgson, PhD
- Phone Number: +1 (617) 963-0105
- Email: Clinical@Corbuspharma.com
Study Contact Backup
- Name: Rodney Carter, BSc
- Email: Clinical@Corbuspharma.com
Study Locations
-
-
-
Barcelona, Spain, 08023
- Not yet recruiting
- Barcelona IOB Hospital Quironsalud (NEXT)
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
Barcelona, Spain, 08035
- Not yet recruiting
- Vall d-Hebron Institut d'Oncologia
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
Madrid, Spain, 28040
- Not yet recruiting
- Fundacion Jimenez Diaz (START)
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
Valencia, Spain, 46010
- Not yet recruiting
- Hospital Clínico Universitario de Valencia
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
-
-
-
-
Adana, Turkey, 83114
- Not yet recruiting
- Adana Numune Egitim ve Arastirma Hastanesi (Adana City Education and Research Hospital)
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
Ankara, Turkey
- Not yet recruiting
- Ankara University
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
Ankara, Turkey
- Not yet recruiting
- Ankara Etlik City Hospital
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
Istanbul, Turkey, 34720
- Not yet recruiting
- İstanbul medeniyet University
-
Contact:
- Rodney Carter
- Email: Clincal@corbuspharma.com
-
-
-
-
-
Birmingham, United Kingdom, B15 2TH
- Not yet recruiting
- University of Birmingham NHS Foundation Trust
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
Cambridge, United Kingdom, CB2 0QQ
- Not yet recruiting
- University of Cambridge NHS Foundation Trust
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
Cardiff, United Kingdom, CF15 7QZ
- Not yet recruiting
- Velindre Cancer Centre
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
Leeds, United Kingdom, LS9 7LP
- Not yet recruiting
- Leeds University Hospitals NHS Trust
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
London, United Kingdom, SE1 9RT
- Not yet recruiting
- Guy's and St Thomas' Clinical Research Facility
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
London, United Kingdom, W12 0NN
- Not yet recruiting
- Imperial Experimental Cancer Medicine Centre
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
Manchester, United Kingdom, M20 4BX
- Not yet recruiting
- The Christie Hospital
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
Southampton, United Kingdom, SO16 6YD
- Not yet recruiting
- University of Southampton
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
Wirral, United Kingdom, CH63 4JY
- Not yet recruiting
- University of Liverpool - Clatterbridge Medical Centre
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
-
-
-
California
-
San Diego, California, United States, 92037
- Not yet recruiting
- Moores Cancer Centre at UC San Diego Health
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
San Francisco, California, United States, 94115
- Not yet recruiting
- Helen Diller Family Comprehensive Cancer Center - UCSF
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Not yet recruiting
- Rocky Mountain Cancer Centres
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Not yet recruiting
- Yale Cancer Center
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
-
Florida
-
Orlando, Florida, United States, 32806
- Not yet recruiting
- Florida Cancer Specialists
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Not yet recruiting
- University of Chicago
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
Hinsdale, Illinois, United States, 60521
- Recruiting
- Hope and Healing Cancer Center
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Not yet recruiting
- Dana-Faber Cancer Institute
-
Contact:
- Rodney Carter
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68506
- Recruiting
- Nebraska Hematology Oncology
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
-
North Carolina
-
Huntersville, North Carolina, United States, 28078
- Recruiting
- Carolina BioOncology Institute
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
-
Texas
-
Tyler, Texas, United States, 75702
- Not yet recruiting
- Texas Oncology
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Not yet recruiting
- Virginia Cancer Specialists
-
Contact:
- Rodney Carter
- Email: Clinical@corbuspharma.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Confirmed diagnosis of select advanced or metastatic nectin-4 expressing solid tumors that have progressed following at least one line of therapy or have no other standard therapy with proven clinical benefit.
Exclusion Criteria:
- Active of uncontrolled CNS metastases
- History of solid tumors other than the diseases under study
- History of and/or current cardiovascular events or conditions in the previous 6 months
- Pre-existing >/= Grade 2 neuropathy
- Hemoglobin A1C (HbA1C) >/= 8%, uncontrolled diabetes mellitus or know diabetic neuropathy
- Active ocular disease at baseline
- Chronic severe liver disease or live cirrhosis
- Interstitial lung disease or pneumonitis within 6 months on initiating treatment on study
- Other significant cormorbidities.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A Dose Escalation - CRB-701 Dose Level 1
CRB-701 Dose level 1, intravenous infusion over 30 mins, Dose schedule 1
|
Nectin-4 targeted Antibody Drug Conjugate (ADC)
|
Experimental: Part A Dose Escalation - CRB-701 Dose Level 2
CRB-701 Dose Level 2, intravenous infusion over 30 mins, Dose schedule 1
|
Nectin-4 targeted Antibody Drug Conjugate (ADC)
|
Experimental: Part A Dose Escalation - CRB-701 Dose Level 3
CRB-701 Dose Level 3, intravenous infusion over 30 mins, dose schedule 1
|
Nectin-4 targeted Antibody Drug Conjugate (ADC)
|
Experimental: Part A Dose Escalation - CRB-701 Dose Level 4
CRB-701 Dose Level 4, intravenous infusion over 30 mins, dose schedule 1
|
Nectin-4 targeted Antibody Drug Conjugate (ADC)
|
Experimental: Part B Dose Optimization: CRB-701 High dose
Selected high dose of CRB-701, intravenous infusion over 30 mins, dose schedule 1
|
Nectin-4 targeted Antibody Drug Conjugate (ADC)
|
Experimental: Part B Dose Optimization: CRB-701 low dose
Selected Low dose of CRB-701, intravenous infusion over 30 mins, once every three weeks
|
Nectin-4 targeted Antibody Drug Conjugate (ADC)
|
Experimental: Part C Dose Expansion - Cohort 1
Recommended Phase 2 dose and schedule of CRB-701, intravenous infusion over 30 mins
|
Nectin-4 targeted Antibody Drug Conjugate (ADC)
|
Experimental: Part C Dose Expansion - Cohort 2
Recommended Phase 2 dose and schedule of CRB-701, intravenous infusion over 30 mins
|
Nectin-4 targeted Antibody Drug Conjugate (ADC)
|
Experimental: Part C Dose Expansion - Cohort 3
Recommended Phase 2 dose of CRB-701 and schedule, intravenous infusion over 30 mins
|
Nectin-4 targeted Antibody Drug Conjugate (ADC)
|
Experimental: Part C Dose Expansion - Cohort 4
Recommended Phase 2 dose of CRB-701 and schedule, intravenous infusion over 30 mins
|
Nectin-4 targeted Antibody Drug Conjugate (ADC)
|
Experimental: Part C Dose Expansion - Cohort 5
Recommended Phase 2 dose of CRB-701 and schedule, intravenous infusion over 30 mins
|
Nectin-4 targeted Antibody Drug Conjugate (ADC)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part A: To confirm the safety and tolerability and determine MTD and PADR for CRB-701
Time Frame: 21 days
|
Occurrence of Dose Limiting Toxicities as defined in the protocol
|
21 days
|
Part B & C : To evaluate efficacy in terms of Disease Control Rate (DCR)
Time Frame: Up to 6 months
|
DCR is the sum of percentage of participants meeting the definition of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) for at least 4 months using RECIST 1.1
|
Up to 6 months
|
Part B & C: To evaluate efficacy in terms of Objective Response Rate (ORR)
Time Frame: Up to 6 months
|
ORR is the percentage of participants that achieve a response (CR + PR) using RECIST 1.1
|
Up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed plasma concentration of CRB-701 [total ADC] (Cmax)
Time Frame: Approximately 9 weeks
|
Maximum observed plasma concentration of total ADC after single and multiple doses
|
Approximately 9 weeks
|
Maximum observed plasma concentration of free MMAE (Cmax)
Time Frame: Approximately 9 weeks
|
Maximum observed plasma concentration of free MMAE after single and multiple doses
|
Approximately 9 weeks
|
Maximum observed plasma concentration of Total CRB-701 antibody [Tab] (Cmax)
Time Frame: Approximately 9 weeks
|
Maximum observed plasma concentration of free MMAE after single and multiple doses
|
Approximately 9 weeks
|
Time to reach Cmax of Total CRB-701 [Total ADC] (Tmax)
Time Frame: Approximately 9 weeks
|
The amount of time to reach Cmax after single and multiple dose administration of CRB-701 (Total ADC)
|
Approximately 9 weeks
|
Time to reach Cmax of free MMAE (Tmax)
Time Frame: Approximately 9 weeks
|
The amount of time to reach Cmax after single and multiple dose administration of free MMAE
|
Approximately 9 weeks
|
Time to reach Cmax of Total CRB-701 antibody [Tab] (Tmax)
Time Frame: Approximately 9 weeks
|
The amount of time to reach Cmax after single and multiple dose administration of Tab
|
Approximately 9 weeks
|
Time to reach Cmax of Total CRB-701 antibody [Tab] (Cmax)
Time Frame: Approximately 9 weeks
|
Maximum observed plasma concentration of free MMAE after single and multiple doses
|
Approximately 9 weeks
|
Total Area Under the plasma concentration-time curve of Total CRB-701 [total ADC] (AUC)
Time Frame: Approximately 9 weeks
|
Maximum observed plasma concentration of free MMAE after single and multiple doses
|
Approximately 9 weeks
|
Total Area Under the plasma concentration-time curve of free MMAE (AUC)
Time Frame: Approximately 9 weeks
|
Area under the plasma concentration versus time curve after single and multiple dose administration of free MMAE
|
Approximately 9 weeks
|
Total Area Under the plasma concentration-time curve of Total CRB-701 antibody [Tab] (AUC)
Time Frame: Approximately 9 weeks
|
Area under the plasma concentration versus time curve after single and multiple dose administration of Tab
|
Approximately 9 weeks
|
Parts A, B, % C: To characterize the safety profile of CRB-701
Time Frame: Up to 6 months
|
Numbers of treatment emergent adverse events with severity determined using NCI CTCAE v5.0 after single or multiple doses of CRB-701 or single and multiple doses of CRB-701 and an anti-PD-(L)1 therapy
|
Up to 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ari Rosenberg, MD, University of Chicago
- Principal Investigator: David Pinato, MD, Imperial College London
- Study Director: Ian Hodgson, PhD, Corbus International Ltd
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor, Adult
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Invitae CorporationRecruitingCancer | Solid Tumor | Solid Tumor, AdultUnited States
-
Sairopa B.V.RecruitingMetastatic Solid Tumor | Solid Tumor, Adult | Refractory CancerUnited States, Moldova, Republic of
-
Institut CurieRecruitingChemotherapy Effect | Solid Tumor, Adult | Solid Tumor, ChildhoodFrance
-
New York Stem Cell Foundation Research InstituteStevens Institute of TechnologyRecruiting
-
JemincareNot yet recruiting
Clinical Trials on CRB-701
-
CephalonCompletedPsoriasisUnited States
-
CephalonCompleted
-
AmgenWithdrawnRelapsed/Refractory Multiple Myeloma
-
BioMarin PharmaceuticalTerminatedLate-onset Pompe DiseaseUnited States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
-
Terns, Inc.Not yet recruitingChronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic PhaseUnited States
-
BioMarin PharmaceuticalCompletedPompe DiseaseUnited States, United Kingdom, France, Australia, Germany
-
BioMarin PharmaceuticalTerminatedPompe DiseaseUnited States, United Kingdom, Australia, France, Germany, New Zealand
-
Ronald HoffmanNational Cancer Institute (NCI); Myeloproliferative Disorders-Research ConsortiumUnknownPolycythemia Vera | Essential Thrombocythemia | MyelofibrosisUnited States
-
CephalonTerminated